India’s ban on antimicrobial fixed-dose combinations: winning the battle, losing the war?

References

• Van Boeckel TP, Gandra S, Ashok A, et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis. 2014;14:742–750.
   PubMed Web of Science ®Google Scholar
• Laxminarayan R, Chaudhury RR. Antibiotic resistance in india: drivers and opportunities for action. PLoS Med. 2016;13: e1001974.
   PubMed Web of Science ®Google Scholar
• Bortone B, Jackson C, Hsia Y, Bielicki J, Magrini N, Sharland M. High global consumption of potentially inappropriate fixed dose combination antibiotics: analysis of data from 75 countries. PLoS ONE. 2021;16: e0241899.
   PubMed Web of Science ®Google Scholar
• Godman B, McCabe H, Leong TD. Fixed dose drug combinations—are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries. Expert Rev Pharmacoecon Outcomes Res. 2020;20:1–26.
   Google Scholar
• Tyers M, Wright GD. Drug combinations: a strategy to extend the life of antibiotics in the 21st century. Nat Rev Microbiol. 2019;17:141–155.
   PubMed Web of Science ®Google Scholar
• Mehta KC, Dargad RR, Borade DM, Swami OC. Burden of antibiotic resistance in common infectious diseases: role of antibiotic combination therapy. J Clin Diagn Res. 2014;8:ME05–08.
   Google Scholar
• Barlow G. Clinical challenges in antimicrobial resistance. Nat Microbiol. 2018;3:258–260.
   PubMed Web of Science ®Google Scholar
• WHO | WHO releases the 2019 AWaRe Classification Antibiotics. World Health Organization. Available at: http://www.who.int/medicines/news/2019/WHO_releases2019AWaRe_classification_antibiotics/en/. Accessed 1 July 2020.
   Google Scholar
• McGettigan P, Roderick P, Kadam A, Pollock A. Threats to global antimicrobial resistance control: centrally approved and unapproved antibiotic formulations sold in India. Br J Clin Pharmacol. 2019;85:59–70.
   PubMed Web of Science ®Google Scholar
• Vendoti D. Decoding the ban on irrational fixed-dose combination drugs in India. Available at: https://www.orfonline.org/research/decoding-the-ban-on-irrational-fixed-dose-combination-drugs-in-india-45835/. Accessed 14 Feb 2021.
   Google Scholar
• Anand P, Kaur N, Verma V, Shafiq N, Malhotra S. Assessment of rationality of available fixed dose combinations of antibiotics in India. Expert Rev Anti-Infect Ther. 2021. https://doi.org/10.1080/14787210.2022.2015324.
   PubMed Web of Science ®Google Scholar
• Hsia Y, Sharland M, Jackson C, Wong ICK, Magrini N, Bielicki JA. Consumption of oral antibiotic formulations for young children according to the WHO Access, Watch, Reserve (AWaRe) antibiotic groups: an analysis of sales data from 70 middle-income and high-income countries. Lancet Infect Dis. 2019;19:67–75.
   PubMed Web of Science ®Google Scholar
• Jackson C, Hsia Y, Bielicki JA, et al. Estimating global trends in total and childhood antibiotic consumption, 2011–2015. BMJ Glob Health. 2019;4: e001241.
   PubMed Web of Science ®Google Scholar
• Farooqui HH, Selvaraj S, Mehta A, Heymann DL. Community level antibiotic utilization in India and its comparison vis-à-vis European countries: evidence from pharmaceutical sales data. PLoS ONE. 2018;13: e0204805.
   PubMed Web of Science ®Google Scholar
• Sulis G, Batomen B, Kotwani A, Pai M, Gandra S. Sales of antibiotics and hydroxychloroquine in India during the COVID-19 epidemic: an interrupted time series analysis. PLoS Med. 2021;18: e1003682.
   PubMed Web of Science ®Google Scholar
• Chaudhuri S, Pradhan R. Re-examining the notion of irrational antimicrobial prescribing in LMICs. Lancet Infect Dis. 2021;21:28–29.
   PubMed Web of Science ®Google Scholar
• Nair M, Zeegers MP, Varghese GM, Burza S. India’s National Action Plan on Antimicrobial Resistance: a critical perspective. J Glob Antimicrob Resist. 2021;27:236–238.
   PubMed Web of Science ®Google Scholar
• Sharma M, Gangakhedkar RR, Bhattacharya S, Walia K. Understanding complexities in the uptake of indigenously developed rapid point-of-care diagnostics for containment of antimicrobial resistance in India. BMJ Glob Health. 2021;6: e006628.
   PubMed Web of Science ®Google Scholar
• Walia K, Madhumathi J, Veeraraghavan B, et al. Establishing antimicrobial resistance surveillance & research network in India: journey so far. Indian J Med Res. 2019;149:164–179.
   PubMed Web of Science ®Google Scholar
• Gandra S, Alvarez-Uria G, Turner P, Joshi J, Limmathurotsakul D, van Doorn HR. Antimicrobial resistance surveillance in low- and middle-income countries: progress and challenges in eight south Asian and southeast Asian countries. Clin Microbiol Rev. 2020;33:e00048–e119.
   PubMed Web of Science ®Google Scholar
• Roy N, Madhiwalla N, Pai SA. Drug promotional practices in Mumbai: a qualitative study. Indian J Med Ethics. 2007;4:57–61.
   PubMedGoogle Scholar
• Sayer B, Bortone B, Sharland M, Hsia Y. Fixed-dose combination antibiotics: the search for evidence using the example of ampicillin-cloxacillin. Br J Clin Pharmacol. 2020. https://doi.org/10.1111/bcp.14711
   Web of Science ®Google Scholar
• Palwe S, Veeraraghavan B, Periasamy H, Khobragade K, Kharat AS. Unorthodox parenteral β-lactam and β-lactamase inhibitor combinations: flouting antimicrobial stewardship and compromising patient care. Antimicrob Agents Chemother. 2020;64:e00168–e220.
   PubMed Web of Science ®Google Scholar